Pozen reported stronger profit and revenue for the third quarter, driven mostly by a $10 million payment the Chapel Hill drug maker received after seeking approval for a new treatment for arthritis.
In June, Pozen got the money from partner AstraZeneca following a filing seeking approval for the medicine from the Food and Drug Administration. Pozen also is seeing increasing revenue from Treximet, a migraine treatment sold by another partner, GlaxoSmithKline.
Pozen's products combine medications to reduce pain and inflammation with fewer gastrointestinal side effects than existing drugs. The company also is developing a safer form of aspirin to treat cardiovascular disease and stroke.